| A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer |
Nature et Objective
A randomized Phase 3b study evaluating nadofaragene firadenovec-vncg (Adstiladrin) versus active observation, with intermediate-risk non-muscle invasive bladder cancer (IR-NMIBC) following a transurethral resection of a bladder tumor. The primary endpoint is recurrence‑free survival, with secondary endpoints including 12‑ and 24‑month RFS and safety. Exploratory measures include biomarker effects and quality of life. Final results are expected in 2031.
Stade de la Maladie: Précoce
Organe: Prostate
Maladie: Cancer de la vessie